Prelude Therapeutics (PRLD) Operating Leases (2021 - 2026)
Prelude Therapeutics (PRLD) posted Operating Leases of $15.0 million for Q1 2026, down 0.56% sequentially from $15.0 million in Q4 2025, and down 2.01% YoY from $15.3 million in Q1 2025.
Prelude Therapeutics (PRLD) Operating Leases (2021 - 2026) Analysis & Trends
Prelude Therapeutics has reported Operating Leases for 6 years, with the latest figure at $15.0 million in Q1 2026.
- Quarterly Operating Leases fell 2.01% year-over-year to $15.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.0 million (down 2.01% YoY) and the FY2025 annual result came in at $15.0 million, down 1.83% from the prior year.
- Operating Leases fell to $15.0 million in Q1 2026 per PRLD's latest filing, from $15.0 million in the prior quarter.
- Over five years, Operating Leases peaked at $16.9 million in Q4 2023 and troughed at $390000.0 in Q1 2022.
- A 5-year average of $14.0 million and a median of $15.3 million in 2025 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2022 and 2025: Operating Leases slumped 53.57% in 2022, then declined 1.2% in 2025.
- Over 5 years, Operating Leases stood at $390000.0 in 2022, then soared by 4230.26% to $16.9 million in 2023, then declined by 9.26% to $15.3 million in 2024, then retreated by 1.83% to $15.0 million in 2025, then decreased by 0.56% to $15.0 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $15.0 million, $15.0 million, and $15.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Prelude Therapeutics | 442.91 Mn | 162.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.87 Mn |
| Mar 31, 2026 | 14.96 Mn |
| Dec 31, 2025 | 15.05 Mn |
| Sep 30, 2025 | 15.13 Mn |
| Jun 30, 2025 | 15.21 Mn |
| Mar 31, 2025 | 15.27 Mn |
| Dec 31, 2024 | 15.33 Mn |
| Sep 30, 2024 | 15.41 Mn |
| Jun 30, 2024 | 15.47 Mn |
| Mar 31, 2024 | 15.45 Mn |
| Dec 31, 2023 | 16.89 Mn |
| Mar 31, 2022 | 390,000.00 |
| Sep 30, 2021 | 312,000.00 |
| Jun 30, 2021 | 543,000.00 |
| Mar 31, 2021 | 840,000.00 |